Chronic granulocytic leukemia, abbreviated as CML, is a common disease of the blood system. Common symptoms are hypothermia, malaise, weight loss, etc. Some patients are asymptomatic and are detected only during physical examination. The tests that must be done are blood routine, bone marrow, chromosome, and BCR-ABL fusion gene. The main treatments are imatinib, hematopoietic stem cell transplantation and general therapy. Gan Silin, Department of Hematology, First Affiliated Hospital of Zhengzhou University Blood routine shows elevated leukocytes, with immature cells seen in manual sorting; bone marrow shows markedly active or extremely active proliferation, with the most significant proliferation in the granulocyte lineage; chromosomes show Ph chromosomes, i.e. t(9;22)(q34;q11); BCR-ABL fusion gene is positive. The above typical chromosomes and fusion genes can be detected in about 95-98% of patients, and the above chromosomes and genes cannot be detected in about 2-5% of patients. Imatinib is the first choice for the treatment of chronic granulocytes, the trade name of Gleevec, a product of Novartis, Switzerland, with a long-term efficiency of about 93%. The next option is hematopoietic stem cell transplantation, formerly known as bone marrow transplantation, which has a cure rate of about 65%-70% (data from the First Affiliated Hospital of Zhengzhou University), with common complications such as graft-versus-host disease (GVHD), hepatic vein occlusion (VOD), interstitial pneumonia, hemorrhagic cystitis, infection, and graft failure. If economic conditions or physical conditions do not allow, the only option is general treatment, which mainly includes hydroxyurea, interferon and chemotherapy. Disclaimer: The above remarks are for reference only and should not be used as a basis for disease diagnosis and treatment. If you have any questions, please visit the clinic for consultation.